UNLABELLED: This feasibility study demonstrates (90)Y quantitative bremsstrahlung imaging of patients undergoing high-dose myeloablative (90)Y-ibritumomab treatment. METHODS: The study includes pretherapy (111)In SPECT/CT and planar whole-body (WB) imaging at 7 d and therapy (90)Y SPECT/CT at 6 d and (90)Y WB imaging at 1 d. Time-activity curves and organ-absorbed doses derived from (90)Y SPECT images were compared with pretherapy (111)In estimates. Organ activities derived from (90)Y WB images at the first day were compared with corresponding pretherapy estimates. RESULTS: Pretherapy (111)In images from 3 patients were similar to the (90)Y images. Differences between absorbed-dose estimates from pretherapy (111)In and (90)Y therapy were within 25%, except for the lungs. Corresponding activity differences derived from WB images were within 25%. Differences were ascribed to incomplete compensation methods and real differences in pharmacokinetics between pretherapy and therapy. CONCLUSION: Quantitative bremsstrahlung imaging to estimate organ activities and absorbed doses is feasible.
UNLABELLED: This feasibility study demonstrates (90)Y quantitative bremsstrahlung imaging of patients undergoing high-dose myeloablative (90)Y-ibritumomab treatment. METHODS: The study includes pretherapy (111)In SPECT/CT and planar whole-body (WB) imaging at 7 d and therapy (90)Y SPECT/CT at 6 d and (90)Y WB imaging at 1 d. Time-activity curves and organ-absorbed doses derived from (90)Y SPECT images were compared with pretherapy (111)In estimates. Organ activities derived from (90)Y WB images at the first day were compared with corresponding pretherapy estimates. RESULTS: Pretherapy (111)In images from 3 patients were similar to the (90)Y images. Differences between absorbed-dose estimates from pretherapy (111)In and (90)Y therapy were within 25%, except for the lungs. Corresponding activity differences derived from WB images were within 25%. Differences were ascribed to incomplete compensation methods and real differences in pharmacokinetics between pretherapy and therapy. CONCLUSION: Quantitative bremsstrahlung imaging to estimate organ activities and absorbed doses is feasible.
Authors: Christian Lohrmann; Hanwen Zhang; Daniel L J Thorek; Pooja Desai; Pat B Zanzonico; Joseph O'Donoghue; Christopher P Irwin; Thomas Reiner; Jan Grimm; Wolfgang A Weber Journal: J Nucl Med Date: 2015-04-03 Impact factor: 10.057
Authors: Yuni K Dewaraja; Eric C Frey; George Sgouros; A Bertrand Brill; Peter Roberson; Pat B Zanzonico; Michael Ljungberg Journal: J Nucl Med Date: 2012-06-28 Impact factor: 10.057
Authors: C Arrichiello; L Aloj; M Mormile; L D'Ambrosio; F Frigeri; C Caracò; M Arcamone; F De Martinis; A Pinto; S Lastoria Journal: Eur J Nucl Med Mol Imaging Date: 2012-01-12 Impact factor: 9.236
Authors: Jianting Yue; Thibault Mauxion; Diane K Reyes; Martin A Lodge; Robert F Hobbs; Xing Rong; Yinfeng Dong; Joseph M Herman; Richard L Wahl; Jean-François H Geschwind; Eric C Frey Journal: Med Phys Date: 2016-10 Impact factor: 4.071
Authors: Hongki Lim; Jeffrey A Fessler; Scott J Wilderman; Allen F Brooks; Yuni K Dewaraja Journal: Phys Med Biol Date: 2018-05-22 Impact factor: 3.609
Authors: Gerrit H van de Maat; Peter R Seevinck; Mattijs Elschot; Maarten L J Smits; Hendrik de Leeuw; Alfred D van Het Schip; Maarten A D Vente; Bernard A Zonnenberg; Hugo W A M de Jong; Marnix G E H Lam; Max A Viergever; Maurice A A J van den Bosch; Johannes F W Nijsen; Chris J G Bakker Journal: Eur Radiol Date: 2012-09-27 Impact factor: 5.315
Authors: Sebastien Baechler; Robert F Hobbs; Ariane Boubaker; Franz Buchegger; Bin He; Eric C Frey; George Sgouros Journal: Med Phys Date: 2012-10 Impact factor: 4.506